Fwd: Coalition urges for more smokefree laws in Oklahoma

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 30, 2008 at 6:26 AM
Subject: Coalition urges for more smokefree laws in Oklahoma
To: mesothelioma77@gmail.com

' Oklahoma is lagging behind in the nationwide effort to ban smoking in the workplace and public places to protect people from second-hand smoke, a coalition of state and private health care agencies said ...

Mon, 30 Jun 2008 05:11:30 GMT

---

Source: http://ocolly.com/2008/06/30/coalition-urges-for-more-smokefree-laws-in-oklahoma/
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: A standout who nearly drowned

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 30, 2008 at 6:26 AM
Subject: A standout who nearly drowned
To: mesothelioma77@gmail.com

Cullen Jones is black. Cullen Jones is a swimmer. Notwithstanding observations from the noted late anthropologist, Al Campanis, who believed African-Americans made lousy swimmers because, "they don't have the ...

Mon, 30 Jun 2008 07:50:54 GMT

---

Source: http://www.ajc.com/sports/content/printedition/2008/06/30/schultz.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Smoking ban triggered the biggest fall in smoking ever seen in England

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 30, 2008 at 6:26 AM
Subject: Smoking ban triggered the biggest fall in smoking ever seen in England
To: mesothelioma77@gmail.com

Smokefree law in England has helped more smokers to quit than ever before and will help prevent an estimated 40,000 deaths over the next 10 years - according to new research being presented in Birmingham ...

Mon, 30 Jun 2008 09:26:00 GMT

---

Source: http://www.news-medical.net/?id=39582
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Accidental fungus leads to promising cancer drug

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 30, 2008 at 6:26 AM
Subject: Accidental fungus leads to promising cancer drug
To: mesothelioma77@gmail.com

A drug developed using nanotechnology and a fungus that contaminated a lab experiment may be broadly effective against a range of cancers, US researchers reported on Sunday.

Mon, 30 Jun 2008 07:45:55 GMT

---

Source: http://www.chinadaily.com.cn/world/2008-06/30/content_6806136.htm
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Study suggests colon cancer vaccine possible

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 30, 2008 at 6:26 AM
Subject: Study suggests colon cancer vaccine possible
To: mesothelioma77@gmail.com

WASHINGTON - A protein found only in the intestines may help lead the way to a vaccine that can treat colon cancers and perhaps other tumors too, U.S. researchers reported on Tuesday.Mice immunized with the ...

Mon, 30 Jun 2008 05:10:00 GMT

---

Source: http://www.topix.net/content/reuters/2008/06/study-suggests-colon-cancer-vaccine-possible
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Derivation and internal validation of a rule to predict hospital admission in prehospital patients.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Derivation and internal validation of a rule to predict hospital admission in prehospital patients.
To: mesothelioma77@gmail.com


[1]Prehosp Emerg Care. 2008 Jul-Sep; 12(3): 314-9
Meisel ZF, Pollack CV, Mechem CC, Pines JM

Objective. To derive and internally validate a simple prediction rule, using routinely collected prehospital patient data, that discriminates between hospital admission and emergency department (ED) discharge for adult patients who arrive by ambulance. Methods. We performed a retrospective cohort study of consecutive adult nontrauma patients transported to two separate EDs over two months by a city-run emergency medical services (EMS) system. We tested whether specific prehospital variables could predict hospital admission using chi-square tests, logistic regression, and receiver-operating characteristic curves. We created a rule to predict the probabilities of hospital admission for individual patients. Results. Of 401 patients, the mean age was 47 years; 60% were black and 32% were white; 51% were female; and 33% were admitted to an inpatient service after evaluation in the ED. Independent predictors of admission were dyspnea (adjusted odds ratio [OR] 6.8; awarded 3 points), chest pain (OR 5.2; 3 points), and dizziness, weakness, or syncope (OR 3.5; 2 points). Also predictive were age >/=60 years (OR 5.5; 3 points) and the prehospital identification of a history of diabetes (OR 1.9; 1 point) or cancer (OR 3.9; 2 points). Patients who had a score of 5 or higher had a greater than 69% chance of being admitted to an inpatient unit. Conclusion. Routinely collected EMS patient information can help predict hospital admission for certain ED patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18584498
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer.
To: mesothelioma77@gmail.com


[1]J Korean Med Sci. 2008 Jun; 23(3): 414-20
Kim YS, Won YS, Park KS, Song BJ, Kim JS, Oh SJ, Jeon HM, Jung SS, Park WC

It is well known that the amplification of the HER2 gene is closely associated with poor prognosis of breast cancer. However, there is controversy about the clinical significance of HER2 according to lymph node status in breast cancer. The aim of this study was to identify the differences in the prognostic significance of HER2 gene amplification according to the stages of breast cancer. We prepared a tissue array for fluorescence in situ hybridization (FISH) with breast cancer specimens from the surgery in 1994 to 1999. Total 338 cases of breast cancer were enrolled and the median follow-up period was 6.3 yr. The detection rates of HER2 gene amplification were as follows: 10.3% in stage I, 22.3% in stage II, and 43.8% in stage III. On survival analyses HER2-positive groups showed worse prognosis in stage III of breast cancer, but not in stage I or II. Multivariate analyses with a Cox-regression model also revealed that HER2 amplification was an independent prognostic factor only in stage III breast cancer. Regarding HER2 gene amplification as a prognostic factor of breast cancer, the clinical significance of the gene was found to be confined to advanced breast cancer.



___
Source: http://www.hubmed.org/display.cgi?uids=18583876
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Identification of Galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Identification of Galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain.
To: mesothelioma77@gmail.com


[1]Cancer Invest. 2008 Jul; 26(6): 615-23
Mayoral MA, Mayoral C, Meneses A, Villalvazo L, Guzman A, Espinosa B, Ochoa JL, Zenteno E, Guevara J

Galectin-3 has been implicated in tumor progression. We demonstrated immunohistochemically that Galectin-3 was negative in normal breast tissue, but it was highly increased in breast cancer and in metastatic tissues to brain. Similarly, histochemistry with mucin-specific lectins showed increased recognition in breast tumor and metastasis with Machaerocereus eruca agglutinin (Fualpha 1,2 (GalNAcalpha 1,3) Galss1,4 in complex mucin) but not for Amaranthus leucocarpus (Galss1,3-GalNAc-alpha 1,0-Ser/Thr) and Arachis hypogaea lectins (Galss1,3GalNAc/Galss1,4GlcNAc). Mucin-type glycans and Galectin-3 colocalized in breast cancer and metastasis, but not in normal tissue, suggesting upregulated biosynthesis of complex O-glycosidically linked glycans and Galectin-3 favor breast cancer progression and brain metastasis.



___
Source: http://www.hubmed.org/display.cgi?uids=18584353
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
To: mesothelioma77@gmail.com


[1]Gynecol Endocrinol. 2008 Jun; 24(6): 331-8
Schubert A, Schulz H, Emons G, Grundker C

Background. The majority of human breast cancers and in addition most breast-cancer cell lines express gonadotropin-releasing hormone (GnRH) receptors. Their proliferation and in addition their bone-directed invasion is time- and dose-dependently reduced by GnRH. Osteolytic metastases are characteristic for breast cancer-derived metastasis. Since the osteolytic activity depends on the receptor activator of nuclear factor-kappaB (NFkappaB) ligand (RANKL)/osteoprotegerin (OPG) ratio, we analyzed RANKL and OPG expression in different breast-cancer cell lines. Methods. Different human breast-cancer cell lines were tested for expression of GnRH receptor, OPG and RANKL. Using a co-culture system of breast-cancer cell lines and human primary osteoblasts (hOB), we analyzed the expression of OPG and RANKL in the GnRH receptor-positive breast-cancer cell line HCC70 co-cultured with or without hOB. In addition, we assessed the effects of GnRH analog treatment on OPG and RANKL mRNA and protein levels. Results. All tested breast-cancer cell lines were GnRH receptor-positive. The majority of these cell lines expressed OPG but not RANKL. The HCC70 breast-cancer cell line derived from an invasive ductal carcinoma with metastases was positive for both OPG and RANKL. The expression of RANKL by HCC70 cells was increased when co-cultured with hOB. Treatment with GnRH analogs reduced the expression of RANKL by HCC70 cells co-cultured with hOB. No effects were observed on breast cancer OPG expression. Conclusions. These data show that the majority of human breast-cancer cell lines express OPG but not RANKL. The HCC70 breast-cancer cell line is RANKL-positive. Co-culture of HCC70 breast cancer cells with hOB increases RANKL expression. Activation of tumor GnRH receptors reduces RANKL expression. These experiments demonstrate that HCC70 breast cancer cells are able to activate osteoclasts directly via RANKL. The interaction between HCC70 breast cancer cells and osteoblasts induces osteoclastogenesis through an increase of RANKL expression. GnRH seems to play an important role by modulating the RANKL expression in HCC70 breast cancer cells.



___
Source: http://www.hubmed.org/display.cgi?uids=18584413
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Stimulation of the human CTP: phosphoethanolamine cytidylyltransferase gene by early growth response protein 1.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Stimulation of the human CTP: phosphoethanolamine cytidylyltransferase gene by early growth response protein 1.
To: mesothelioma77@gmail.com


[1]J Lipid Res. 2008 Jun 26;
Zhu L, Johnson C, Bakovic M

Change in phosphoethanolamine pool size in tumor tissues is an important indicator for tumor prognosis and drug therapy efficacy. Phosphoethanolamine is the substrate of the regulatory enzyme CTP:phosphoethanolamine cytidylyltransferase (ECT) in the de novo biosynthesis of phosphatidylethanolamine (PE). Metabolic labeling with 14C-ethanolamine revealed a reduced ECT activity in MCF-7 breast cancer cells, which led to an accumulation of phosphoethanolamine and a decrease in PE synthesis in comparison with MCF-10A mammary epithelial cells. The enhanced ECT activity in MCF-10A cells was due to significantly elevated CTP:phosphoethanolamine cytidylyltransferase gene (PCYT2) expression, at the level of promoter activity, mRNA and protein content. The early growth response protein 1 (EGR1) could account for most of the elevated ECT activity in MCF-10A cells relative to MCF-7 cells, as evidenced by promoter-luciferase reporter assays, gel-shift analyses and by alterations in the EGR1 gene expression. In MCF-7 cells EGR1 is present at lower levels and the basal PCYT2 promoter activity is maintained by proximal CAAT and GC regions and by elevated nuclear NFB activity. Together, these data demonstrate that EGR1 is an important transcriptional stimulator of the human PCYT2 and that conditions which modify EGR1 also affect the function of ECT and consequently PE synthesis.



___
Source: http://www.hubmed.org/display.cgi?uids=18583706
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Identification, and functional analysis of Ska2 interaction with the glucocorticoid receptor.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Identification, and functional analysis of Ska2 interaction with the glucocorticoid receptor.
To: mesothelioma77@gmail.com


[1]J Endocrinol. 2008 Jun 26;
Ray D, Rice L, Waters C, Eccles J, Garside H, Sommer P, Kay P, Blackhall F, Zeef L, Telfer B, Stratford I, Clarke R, Singh D, White A, Stevens A

Glucocorticoid receptors (GR) have profound anti-survival effects on human small cell lung cancer (SCLC). To explore the basis of these effects, protein partners for GR were sought using a yeast two-hybrid screen. We discovered a novel gene, FAM33A, subsequently identified as a Ska1 partner and involved in mitosis, and so renamed Ska2. We produced an anti-peptide antibody which specifically recognized full-length, human Ska2 to measure expression in human cell lines, and tissues. There was wide variation in expression across multiple cell lines, but none detected in the liver cell line HepG2. A xenograft model of human SCLC had intense staining and archival tissue revealed Ska2 in several human lung, and breast tumours. Ska2 was found in the cytoplasm, where it co-localised with GR but nuclear expression of Ska 2 was seen in breast tumours. Ska2 overexpression increased glucocorticoid transactivation in HepG2 cells while Ska2 knockdown in A549 human lung epithelial cells decreased transactivation and prevented dexamethasone inhibition of proliferation. Glucocorticoid treatment decreased Ska2 protein levels in A549 cells, as did staurosporin, phorbol ester, and trichostatin A; all agents that inhibit cell proliferation. Overexpression of Ska2, potentiated the proliferative response to IGF-I exposure, and knockdown with shRNA caused cells to arrest in mitosis. Ska2 has recently been identified in HeLa S3 cells as part of a complex which is critical for spindle checkpoint silencing and exit from mitosis. Our new data show involvement in cell proliferation and glucocorticoid signaling; with implications for understanding how glucocorticoids impact on cell fate.



___
Source: http://www.hubmed.org/display.cgi?uids=18583474
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [High-risk situation - which is the best chemotherapy?]

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: [High-risk situation - which is the best chemotherapy?]
To: mesothelioma77@gmail.com


[1]Gynakol Geburtshilfliche Rundsch. 2008; 48(3): 118-29
von Minckwitz G

High-risk situations in early breast cancer concern patients with less than 3 involved lymph nodes but additional risk factors as well as patients with more than 3 involved lymph nodes. For the first group, new risk assessment methods to better identify the need for chemotherapy with or without a taxane or with a taxane instead of an anthracycline are needed. For the second group, further improvement of anthracycline- or taxane-containing chemotherapy regimens is warranted. Current approaches include the sequential or simultaneous use of these groups of agents, the combination with antimetabolites, antibodies or small molecules, the neoadjuvant use of chemotherapy as well as dose-dense and dose-escalated chemotherapy regimens.



___
Source: http://www.hubmed.org/display.cgi?uids=18566528
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [Fundamental advances in the adjuvant systemic therapy of breast cancer]

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: [Fundamental advances in the adjuvant systemic therapy of breast cancer]
To: mesothelioma77@gmail.com


[1]Gynakol Geburtshilfliche Rundsch. 2008; 48(3): 111-2
Fink D, Lang U, Kimmig R

In the last few decades, the notion of breast cancer has developed from a local disease rather to a systemic illness. Today radical operations can mostly be avoided by breast-conserving techniques and sentinel lymph node dissection. By the use of cytostatic and endocrine systemic therapies, an essential gain in overall survival could be obtained, too. High-risk situations can be determined and dealt with accordingly by adequate systemic therapies. Current approaches include the sequential or simultaneous use of anthracyclines and taxanes, the combination with antimetabolites, antibodies and tyrosine kinase inhibitors as well as dose-dense chemotherapeutic regimens. In the adjuvant treatment of breast cancer of postmenopausal receptor-positive patients, tamoxifen is not the gold standard anymore. An aromatase inhibitor should be used at any rate.



___
Source: http://www.hubmed.org/display.cgi?uids=18566526
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Sideshow: Winehouse's lung troubles

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Sideshow: Winehouse's lung troubles
To: mesothelioma77@gmail.com

Amy Winehouse , 24, who was rushed to a London hospital after collapsing at home on June 16, must quit drugs and cigarettes or risk losing her voice - or her life - her father told the Sunday Mirror this ...

Tue, 24 Jun 2008 09:45:16 GMT

---

Source: http://www.philly.com/inquirer/columnists/20080624_Sideshow__Winehouse_s_lung_troubles.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Some Vegetables Cut Bladder Cancer Risk

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Some Vegetables Cut Bladder Cancer Risk
To: mesothelioma77@gmail.com

Cruciferous vegetables -- broccoli, cauliflower, cabbage, Brussels sprouts, bok choy and kale -- may reduce bladder cancer risk, U.S. researchers said.

Tue, 24 Jun 2008 08:02:30 GMT

---

Source: http://www.redorbit.com/news/health/1446959/some_vegetables_cut_bladder_cancer_risk/index.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Cancer-stricken Paul Newman is frail but full of fight (Daily Mail)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Cancer-stricken Paul Newman is frail but full of fight (Daily Mail)
To: mesothelioma77@gmail.com


Gaunt and frail, this is Paul Newman days after it emerged he is suffering from cancer. But his blue eyes, hidden behind dark glasses, are as steely as ever.

Mon, 23 Jun 2008 02:44:35 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=13hstch8b/*http%3A//www.mailonsunday.co.uk/tvshowbiz/article-1028562/Cancer-stricken-Paul-Newman-frail-fight.html?ITO=1490
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Howie Dorough's Father Dies

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Howie Dorough's Father Dies
To: mesothelioma77@gmail.com

Backstreet Boy Howie Dorough is mourning the loss of his father, Hoke, who died in his sleep.

Tue, 24 Jun 2008 08:52:45 GMT

---

Source: http://www.magic1079.com/cc-common/mainheadlines3.html?feed=104762&article=3865757
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Friends rally to help Elmiran dying of cancer

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Friends rally to help Elmiran dying of cancer
To: mesothelioma77@gmail.com

Butch Kelsey is dying. The lung cancer is working away at his lungs, and he knows the end is coming.

Tue, 24 Jun 2008 06:44:15 GMT

---

Source: http://www.stargazette.com/apps/pbcs.dll/article?AID=/20080624/COLUMNIST05/806240329
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Wyeth cancer lawsuit winner dies in Nevada (KABC-TV Los Angeles)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Wyeth cancer lawsuit winner dies in Nevada (KABC-TV Los Angeles)
To: mesothelioma77@gmail.com


Pamela Forrester was 65-years-old and under hospice care for lung cancer when she died Thursday.

Sun, 22 Jun 2008 15:11:38 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12cnq1e4f/*http%3A//abclocal.go.com/kabc/story?section=news/national_world&id=6220637
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Finger Clubbing Mystery Solved, Hippocrates Nods Head in Approval

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Finger Clubbing Mystery Solved, Hippocrates Nods Head in Approval
To: mesothelioma77@gmail.com

What do Hippocrates and the scientists of University of Leeds have in common? They were all equally mystified by the riddle of the seemingly unexplainable "finger clubbing" condition.

Sun, 22 Jun 2008 13:53:28 GMT

---

Source: http://inventorspot.com/articles/finger_clubbing_mystery_solved_hippocrates_nods_head_approval_14134
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties.
To: mesothelioma77@gmail.com


[1]J Immunol. 2008 Jul 1; 181(1): 146-54
Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN

HER-2/neu oncoprotein is overexpressed in a variety of human tumors and is associated with aggressive disease. Immunogenic HER-2/neu CTL epitopes have been used as vaccines for the treatment of HER-2/neu positive malignancies with limited success. By applying prediction algorithms for MHC class I ligands and proteosomal cleavages, in this study, we describe the identification of HER-2/neu decamer LIAHNQVRQV spanning residues 85-94 (HER-2(10(85))). HER-2(10(85)) proved to bind with high affinity to HLA-A2.1 and was stable for 4 h in an off-kinetics assay. This peptide was immunogenic in HLA-A2.1 transgenic (HHD) mice inducing peptide-specific CTL, which responded to tumor cell lines of various origin coexpressing human HER-2/neu and HLA-A2.1. This demonstrates that HER-2(10(85)) is naturally processed from endogenous HER-2/neu. Five of sixteen HER-2/neu(+) HLA-A2.1(+) breast cancer patients analyzed had HER-2(10(85))-reactive T cells ranging from 0.35-0.70% of CD8(+) T cells. Depletion of T regulatory cells from PBMC enabled the rapid expansion of HLA-A2.1/HER-2(10(85))pentamer(+)/CD8(+) cells (PENT(+)/CD8(+)), whereas significantly lower numbers of CTL could be generated from unfractionated PBMC. HER-2(10(85))-specific human CTL recognized the HER-2/neu(+) HLA-A2.1(+) tumor cell line SKBR3.A2, as determined by IFN-gamma intracellular staining and in the high sensitivity CD107alpha degranulation assay. Finally, HER-2(10(85)) significantly prolonged the survival of HHD mice inoculated with the transplantable ALC.A2.1.HER tumor both in prophylactic and therapeutic settings. These data demonstrate that HER-2(10(85)) is an immunogenic peptide, capable of eliciting CD8-mediated responses in vitro and in vivo, providing the platform for further exploitation of HER-2(10(85)) as a possible target for anticancer immunotherapy.



___
Source: http://www.hubmed.org/display.cgi?uids=18566379
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Emodin azide methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Emodin azide methyl anthraquinone derivative triggers mitochondrial-dependent cell apoptosis involving in caspase-8-mediated Bid cleavage.
To: mesothelioma77@gmail.com


[1]Mol Cancer Ther. 2008 Jun; 7(6): 1688-97
Yan Y, Su X, Liang Y, Zhang J, Shi C, Lu Y, Gu L, Fu L

AMAD, an emodin azide methyl anthraquinone derivative, was extracted from the nature giant knotweed rhizome of traditional Chinese herbs. Here, we investigated the anticancer activities and signaling pathways implicated in AMAD-induced apoptosis in human breast cancer cell lines MDA-MB-453 and human lung adenocarcinoma Calu-3 cells. AMAD was found to have a potent cytotoxic effect on both cell lines. Hoechst 33258 staining and Annexin V/propidium iodide double staining exhibited the typical nuclear features of apoptosis and increased the proportion of apoptotic Annexin V-positive cells in a dose-dependent manner, respectively. Moreover, this apoptotic induction was associated with a collapse of the mitochondrial membrane potential and activated caspases (cysteine aspartase) cascade involving in caspase-8, caspase-9, caspase-3, and poly(ADP-ribose) polymerase cleavage in a concentration-dependent manner. It was noteworthy that AMAD also effectively cleaved Bid, a BH3 domain-containing proapoptotic Bcl-2 family member, and induced the subsequent release of cytochrome c from mitochondria into the cytosol. Furthermore, suppression of caspase-8 activity with Z-IETD-FMK partially inhibited release of cytochrome c and Bid cleavage induced by AMAD, whereas exposure to Z-LETD-FMK, a caspase-9 inhibitor, had no effect. Additionally, there was significant change in other mitochondrial membrane proteins triggered by AMAD, such as Bcl-xl and Bad. It was intriguing that AMAD decreased the generation of reactive oxygen species in both cell lines. DNA-binding assay exhibited apoptosis induced by AMAD was not involved in intercalating to DNA. Taken together, these data suggested that AMAD induced apoptosis via a mitochondrial pathway involving caspase-8/Bid activation in both cell lines. [Mol Cancer Ther 2008;7(6):1688-97].



___
Source: http://www.hubmed.org/display.cgi?uids=18566240
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Unknown primary cancer sites

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Unknown primary cancer sites
To: mesothelioma77@gmail.com

In 2005 cancers of unknown primary site represented around 4% of all new cases in New South Wales.

Tue, 24 Jun 2008 08:44:19 GMT

---

Source: http://www.abc.net.au/rn/healthreport/stories/2008/2279761.htm
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: GSK releases cancer genomic data via caBIG

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: GSK releases cancer genomic data via caBIG
To: mesothelioma77@gmail.com

Researchers at academic institutions, small research facilities and non-profit organizations may benefit by not having to incur the prohibitive cost and time involved in identifying and cataloging each cell ...

Tue, 24 Jun 2008 05:48:08 GMT

---

Source: http://www.earlham.edu/~peters/fos/2008/06/gsk-releases-cancer-genomic-data-via_876.html
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Racing to raise awareness, and find a cure

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Racing to raise awareness, and find a cure
To: mesothelioma77@gmail.com

At its bottom line, the annual event aims to raise millions of dollars. See a gallery of photos from Saturday's race But at its heart, the annual Komen Puget Sound Race for the Cure also holds a more personal ...

Sun, 22 Jun 2008 06:33:00 GMT

---

Source: http://seattlepi.nwsource.com/local/367969_race22.html?source=rss
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Singer Amy Winehouse has Lung Damage and Irregular Heartbeat, Docs Say: 'Stop Drugs or Die'

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Singer Amy Winehouse has Lung Damage and Irregular Heartbeat, Docs Say: 'Stop Drugs or Die'
To: mesothelioma77@gmail.com

Amy Winehouse's hard partying ways have officially caught up with her. That accordinding to Jovie Baclayon of E! Online.

Sun, 22 Jun 2008 12:32:42 GMT

---

Source: http://www.nowpublic.com/culture/singer-amy-winehouse-has-lung-damage-and-irregular-heartbeat-docs-say-stop-drugs-or-die
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Man's own cells killing his skin cancer

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Man's own cells killing his skin cancer
To: mesothelioma77@gmail.com

Roland Piquepaille writes "As you probably know, melanoma is one of the deadliest forms of skin cancer, usually caused by too much exposure to the sun.

Sun, 22 Jun 2008 18:05:18 GMT

---

Source: http://slashdot.org/firehose.pl?op=view&id=734047
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Hey, Buddy, Can I Bum a Snus Off You?

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Hey, Buddy, Can I Bum a Snus Off You?
To: mesothelioma77@gmail.com

Faced with rising taxes for cigarettes -- in New York the price of a pack hit $9 -- and ever-tightening smoking bans in places such as Los Angeles, where a bill threatens to force smokers out of all outdoor ...

Sun, 22 Jun 2008 20:00:47 GMT

---

Source: http://adage.com/article.php?article_id=127913
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: LegalView Warns of the Increased Risk of Asbestos Exposure in...

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: LegalView Warns of the Increased Risk of Asbestos Exposure in...
To: mesothelioma77@gmail.com

LegalView updated mesothelioma blog readers to the severe consequences that may exist in the aftermath of environmental destruction such as tornadoes or storms.

Tue, 24 Jun 2008 09:12:20 GMT

---

Source: http://www.pr.com/press-release/91719
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Bothell biotech firm Alder gets ready to grow in antibodies

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Bothell biotech firm Alder gets ready to grow in antibodies
To: mesothelioma77@gmail.com

Alder Biopharmaceuticals Chief Executive Randall Schatzman watches a procedure being done by research associate Katie Olson.

Tue, 24 Jun 2008 07:40:40 GMT

---

Source: http://seattletimes.nwsource.com/html/biotech/2008013843_alder24.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Brayton Purcell Peddlers Will Join the 'Breathe Easy Ride' to Benefit the American Lung Association

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Brayton Purcell Peddlers Will Join the 'Breathe Easy Ride' to Benefit the American Lung Association
To: mesothelioma77@gmail.com

Brayton Purcell's team, the 'Brayton Purcell Peddlers,' are preparing to ride for clean air, smoke-free kids, and a cure for lung disease.

Tue, 24 Jun 2008 07:00:00 GMT

---

Source: http://www.topix.net/content/prweb/2008/06/brayton-purcell-peddlers-will-join-the-breathe-easy-ride-to-benefit-the-american-lung-association
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.

---------- Forwarded message ----------
From: Connotea: Bookmarks matching tags breast and cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
To: mesothelioma77@gmail.com


[1]

[2]Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.

Gert G Van den Eynden et al.

Breast cancer research and treatment 95 (3), 219-28 (Feb 2006)

info:pmid/16244790 | info:doi/10.1007/s10549-005-9002-1

Posted by [3]kavitaphd to [4]Eynden [5]Gert [6]den [7]van [8]reseach [9]discussion [10]2006 [11]breast [12]& [13]treatment [14]G [15]cancer on [16]Mon Jun 23 2008 at 14:34 UTC | [17]info | related

kavitaphd

___
Source: http://www.connotea.org/user/kavitaphd/uri/e4bdda7ff289f3c4dd27b391c26f90d6
--
 ~
Powered by [21]RssFwd, a service of [22]Blue Sky Factory, Inc

 

Fwd: Cancer death rate higher in North of England

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Cancer death rate higher in North of England
To: mesothelioma77@gmail.com

If you live in the North, you are 20 per cent more likely to die from cancer than anywhere else in Britain.

Tue, 17 Jun 2008 07:00:00 GMT

---

Source: http://www.mirror.co.uk/news/healthnews/2008/06/17/cancer-death-rate-higher-in-north-of-england-89520-20610001/
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Male-only support group helps cancer patients stay strong

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Male-only support group helps cancer patients stay strong
To: mesothelioma77@gmail.com

Doug Scott pushed around a pin that represents men supporting men Thursday, June 12, 2008, during a men's cancer support group meeting at the American Cancer Society in Cape Girardeau.

Tue, 24 Jun 2008 08:35:24 GMT

---

Source: http://www.semissourian.com/apps/pbcs.dll/article?AID=/20080624/NEWS01/275083373/1001
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Why we should all read the "Daily Mail"

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Why we should all read the "Daily Mail"
To: mesothelioma77@gmail.com

"I found it on the train" or "They delivered the wrong paper this morning. I normally get The Times". Truth be told, apart from the title, The Times is increasingly indistinguishable from the Daily Mail.

Sun, 22 Jun 2008 18:39:51 GMT

---

Source: http://nhsblogdoc.blogspot.com/2008/06/why-we-should-all-read-daily-mail.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Blues legend Hubert Sumlin to play 202 Market

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Blues legend Hubert Sumlin to play 202 Market
To: mesothelioma77@gmail.com

Annie Leibovitz shot this portrait of Hubert Sumlin at the Maple Leaf Bar in New Orleans for her 2003 book, "American Music." Guitar icon Hubert Sumlin's path to the Blues Hall of Fame began atop a stack of ...

Tue, 24 Jun 2008 07:11:23 GMT

---

Source: http://www.roanoke.com/extra/wb/166888
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: LegalView Warns of Increased Risk of Asbestos Exposure in Aftermath of Environmental Storms and Destruction (PRWeb via Yahoo! News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: LegalView Warns of Increased Risk of Asbestos Exposure in Aftermath of Environmental Storms and Destruction (PRWeb via Yahoo! News)
To: mesothelioma77@gmail.com


LegalView updated mesothelioma blog readers to the severe consequences that may exist in the aftermath of environmental destruction such as tornadoes or storms. LegalView specifically reminded Kansas victims to be aware of the risk for asbestos exposure associated with cleaning up debris after a severe storm season, which left homes and buildings damaged.

Mon, 23 Jun 2008 07:01:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=1222dq08a/*http%3A//news.yahoo.com/s/prweb/20080623/bs_prweb/prweb1045494_1
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Where's the Outrage?

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Where's the Outrage?
To: mesothelioma77@gmail.com

UCLA doctors put her on a list for a liver transplant Dec. 6 and a liver became available four days later, the family said.

Sun, 22 Jun 2008 19:44:10 GMT

---

Source: http://rightwingnews.com/mt331/2008/06/wheres_the_outrage.php
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Healthcare notes for June 24, 2008

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Healthcare notes for June 24, 2008
To: mesothelioma77@gmail.com

The Ms. Missouri Nursing Home Pageant was held recently at Terrible's Frontier Casino in St.

Tue, 24 Jun 2008 05:42:38 GMT

---

Source: http://stjoenews.net/news/2008/jun/24/healthcare-notes-june-24-2008/
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: [Predicting response to therapy in breast cancer]

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: [Predicting response to therapy in breast cancer]
To: mesothelioma77@gmail.com


[1]Gynakol Geburtshilfliche Rundsch. 2008; 48(3): 113-7
Strunz K, Deissler H, Kreienberg R, Sauer G

Molecular staging of breast cancer with microarray technologies leads to different gene expression profiles distinguishing 4 special groups: luminal A and B subtype, HER2 subtype and basal subtype. These 4 groups show a different prognosis as well as different behaviours and responses to adjuvant therapy. The development of gene expression profiles to classify breast cancer may contribute to the targeted institution of adjuvant therapies. Especially the 21-gene recurrence score (Oncotype DX) and the 70-gene profile (Mamma-print) have become intensively examined prognostic and predictive tools. As chemotherapy is an integral component of adjuvant therapy in early breast cancer but estrogen-receptor-positive breast cancer is the most common type, patient selection for adjuvant chemotherapy is of particular interest. In instances when the benefit from chemotherapy seems modest, there is a decision making tool beside traditional histopathological parameters that might provide additional objective prognostic and predictive information. Those genomic decision making approaches may yield more rational treatment choices and may keep patients from systemic treatment modalities of lower value.



___
Source: http://www.hubmed.org/display.cgi?uids=18566527
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells.
To: mesothelioma77@gmail.com


[1]J Immunol. 2008 Jul 1; 181(1): 808-21
Vasir B, Wu Z, Crawford K, Rosenblatt J, Zarwan C, Bissonnette A, Kufe D, Avigan D

Vaccination of patients with dendritic cell (DC)/breast carcinoma fusions stimulated antitumor immune responses in a majority of patients with metastatic disease but only a subset demonstrate evidence of tumor regression. To define the factors that limit vaccine efficacy, we examined the biological characteristics of DC/breast carcinoma fusions as APCs and the nature of the vaccine-mediated T cell response. We demonstrate that fusion of DCs with breast carcinoma cells up-regulates expression of costimulatory and maturation markers and results in high levels of expression of IL-12 consistent with their role as activated APCs. Fusion cells also express the chemokine receptor CCR7, consistent with their ability to migrate to the draining lymph node. However, DC/breast cancer fusions stimulate a mixed T cell response characterized by the expansion of both activated and regulatory T cell populations, the latter of which is characterized by expression of CTLA-4, FOXP3, IL-10, and the suppression of T cell responses. Our results demonstrate that IL-12, IL-18, and TLR 9 agonist CpG oligodeoxynucleotides reduce the level of fusion-mediated regulatory T cell expansion. Our results also demonstrate that sequential stimulation with DC/breast carcinoma fusions and anti-CD3/CD28 results in the marked expansion of activated tumor-specific T cells. These findings suggest that DC/breast carcinoma fusions are effective APCs, but stimulate inhibitory T cells that limit vaccine efficacy. In contrast, exposure to TLR agonists, stimulatory cytokines, and anti-CD3/CD28 enhances vaccine efficacy by limiting the regulatory T cell response and promoting expansion of activated effector cells.



___
Source: http://www.hubmed.org/display.cgi?uids=18566447
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Lung disease Amy Winehouse told to stop smoking drugs or die.

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Lung disease Amy Winehouse told to stop smoking drugs or die.
To: mesothelioma77@gmail.com

Warned she could die ... Amy Winehouse looks out the window of her North London home on June 11, 2008.

Mon, 23 Jun 2008 01:17:25 GMT

---

Source: http://www.theage.com.au/news/people/amy-winehouse-told-to-stop-smoking-drugs-or-die/2008/06/23/1214073097985.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Once-fatal cancers now treated as a chronic disease

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Once-fatal cancers now treated as a chronic disease
To: mesothelioma77@gmail.com

To see Barry Cooper working out at the YMCA in Brooklyn, New York, every morning before going to work as a patent lawyer, you would be unlikely to guess that he has cancer.

Sun, 22 Jun 2008 21:01:48 GMT

---

Source: http://www.iht.com/articles/2008/06/19/arts/snbrody.php
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Woman Who Won Millions From Wyeth In Cancer Suit Dies

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Woman Who Won Millions From Wyeth In Cancer Suit Dies
To: mesothelioma77@gmail.com

One of three Nevada women who were awarded millions in damages in a drug-company lawsuit has died.

Sun, 22 Jun 2008 20:05:33 GMT

---

Source: http://www.todaysthv.com/news/health/story.aspx?storyid=67892
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Resection of a locally advanced hilar tumor and the hepatic artery after stepwise hepatic arterial embolization: A case report.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Resection of a locally advanced hilar tumor and the hepatic artery after stepwise hepatic arterial embolization: A case report.
To: mesothelioma77@gmail.com


[1]World J Gastroenterol. 2008 Jun 14; 14(22): 3587-90
Miura T, Hakamada K, Ohata T, Narumi S, Toyoki Y, Nara M, Ishido K, Ohashi M, Akasaka H, Jin H, Kubo N, Ono S, Kijima H, Sasaki M

We herein report a case of a hilar tumor with extensive invasion to the proper hepatic artery, which was successfully treated with a radical resection in a 57-year-old female patient after a stepwise hepatic arterial embolization. She underwent right colectomy and partial hepatectomy for advanced colon cancer two years ago and radiofrequency ablation therapy for a liver metastasis one year ago, respectively. A recurrent tumor was noted around the proper hepatic artery with invasion to the left hepatic duct and right hepatic artery 7 mo previously. We planned a radical resection for the patient 5 mo after the absence of tumor progression was confirmed while he was undergoing chemotherapy. To avoid surgery-related liver failure, we tried to promote the formation of collateral hepatic arteries after stepwise arterial embolization of the posterior and anterior hepatic arteries two weeks apart. Finally, the proper hepatic artery was occluded after formation of collateral flow from the inferior phrenic and superior mesenteric arteries was confirmed. One month later, a left hepatectomy with hepatic arterial resection was successfully performed without any major complications.



___
Source: http://www.hubmed.org/display.cgi?uids=18567092
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Man saved by new cancer treatment

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Man saved by new cancer treatment
To: mesothelioma77@gmail.com

An Oregon man, given less than a year to live, had a complete remission of advanced deadly skin cancer after an experimental treatment that revved up his immune system to fight the tumours.

Sat, 21 Jun 2008 07:00:00 GMT

---

Source: http://timestranscript.canadaeast.com/rss/article/331771
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Enzymatic metabolites of lycopene induce Nrf2-mediated expression of phase II detoxifying/antioxidant enzymes in human bronchial epithelial cells.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Enzymatic metabolites of lycopene induce Nrf2-mediated expression of phase II detoxifying/antioxidant enzymes in human bronchial epithelial cells.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 19;
Lian F, Wang XD

Lycopene can be cleaved by carotene 9',10'-oxygenase at its 9',10' double bond to form apo-10'-lycopenoids, including apo-10'-lycopenal, -lycopenol and -lycopenoic acid. The latter has been recently shown to inhibit lung carcinogenesis both in vivo and in vitro, however, the mechanism(s) underlying this protection is not well defined. In the present study, we report that treatment with apo-10'-lycopenoic acid, in a time- and dose-dependent manner, results in the nuclear accumulation of transcription factor Nrf2 (nuclear factor E(2)-related factor 2) protein in BEAS-2B human bronchial epithelial cells. The activation of Nrf2 by apo-10'-lycopenoic acid is associated with the induction of phase II detoxifying/antioxidant enzymes including heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate-cysteine ligases in BEAS-2B cells. Furthermore, apo-10'-lycopenoic acid treatment increased total intracellular glutathione levels and suppressed both endogenous reactive oxygen species generation and H(2)O(2)-induced oxidative damage in BEAS-2B cells. In addition, both apo-10'-lycopenol and apo-10'-lycopenal induced heme oxygenase-1 gene expression in BEAS-2B cells. These data strongly suggest that the anti-carcinogenic and antioxidant functions of lycopene may be mediated by apo-10'-lycopenoids via activating Nrf2 and inducing phase II detoxifying/antioxidant enzymes. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18566994
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.
To: mesothelioma77@gmail.com


[1]Mol Cancer Ther. 2008 Jun; 7(6): 1472-82
Lavallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM

Clinical studies using the microtubule-targeting agent 2-methoxyestradiol (2ME2; Panzem) in cancer patients show that treatment is associated with clinical benefit, including prolonged stable disease, complete and partial responses, and an excellent safety profile. Studies have shown that 2ME2 is metabolized by conjugation at positions 3 and 17 and oxidation at position 17. To define structure-activity relationships for these positions of 2ME2 and to generate metabolically stable analogues with improved anti-tubulin properties, a series of analogues was generated and three lead analogues were selected, ENMD-1198, ENMD-1200, and ENMD-1237. These molecules showed improved metabolic stability with >65% remaining after 2-h incubation with hepatocytes. Pharmacokinetic studies showed that oral administration of the compounds resulted in increased plasma levels compared with 2ME2. All three analogues bind the colchicine binding site of tubulin, induce G(2)-M cell cycle arrest and apoptosis, and reduce hypoxia-inducible factor-1alpha levels. ENMD-1198 and ENMD-1200 showed improved in vitro antiproliferative activities. Significant reductions in tumor volumes compared with vehicle-treated mice were observed in an orthotopic breast carcinoma (MDA-MB-231) xenograft model following daily oral treatment with all compounds (ANOVA, P

___
Source: http://www.hubmed.org/display.cgi?uids=18566218
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Finding early invasive breast cancers: a practical approach.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Finding early invasive breast cancers: a practical approach.
To: mesothelioma77@gmail.com


[1]Radiology. 2008 Jul; 248(1): 61-76
Harvey JA, Nicholson BT, Cohen MA

Detection of early invasive breast cancer is important, as patient survival is high when the cancer is 2 cm or smaller. Invasive breast cancers typically manifest mammographically as focal asymmetries or masses. Strategies for detecting focal asymmetries and masses on screening mammograms include side-by-side comparison, looking for parenchymal contour deformity, close inspection of the retromammary fat, identifying the presence of associated findings, and comparison with prior mammograms. Focal asymmetries are often normal but are concerning when there is distortion of the normal breast architecture. Masses and focal asymmetries are best evaluated in the diagnostic setting by using spot compression and true lateral views and, frequently, ultrasonography. Management of a lesion depends on the worst imaging feature. Indications for an assessment of probably benign findings are very specific but are often misapplied. This review for residents provides a practical approach to the detection and management of breast masses and focal asymmetries.



___
Source: http://www.hubmed.org/display.cgi?uids=18566169
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: ISG15 as a novel tumor biomarker for drug sensitivity.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: ISG15 as a novel tumor biomarker for drug sensitivity.
To: mesothelioma77@gmail.com


[1]Mol Cancer Ther. 2008 Jun; 7(6): 1430-9
Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, Scott GL, Giovanella BC, Liu LF

Tumor cells are known to exhibit highly varied sensitivity to camptothecins (CPT; e.g., irinotecan and topotecan). However, the factors that determine CPT sensitivity/resistance are largely unknown. Recent studies have shown that the ubiquitin-like protein, IFN-stimulated gene 15 (ISG15), which is highly elevated in many human cancers and tumor cell lines, antagonizes the ubiquitin/proteasome pathway. In the present study, we show that ISG15 is a determinant for CPT sensitivity/resistance possibly through its effect on proteasome-mediated repair of topoisomerase I (TOP1)-DNA covalent complexes. First, short hairpin RNA-mediated knockdown of either ISG15 or UbcH8 (major E2 for ISG15) in breast cancer ZR-75-1 cells decreased CPT sensitivity, suggesting that ISG15 overexpression in tumors could be a factor affecting intrinsic CPT sensitivity in tumor cells. Second, the level of ISG15 was found to be significantly reduced in several tumor cells selected for resistance to CPT, suggesting that altered ISG15 regulation could be a significant determinant for acquired CPT resistance. Parallel to reduced CPT sensitivity, short hairpin RNA-mediated knockdown of either ISG15 or UbcH8 in ZR-75-1 cells resulted in increased proteasomal degradation of CPT-induced TOP1-DNA covalent complexes. Taken together, these results suggest that ISG15, which interferes with proteasome-mediated repair of TOP1-DNA covalent complexes, is a potential tumor biomarker for CPT sensitivity. [Mol Cancer Ther 2008;7(6):1430-9].



___
Source: http://www.hubmed.org/display.cgi?uids=18566215
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 17;
Speel EJ, van de Wouw AJ, Claessen SM, Haesevoets A, Hopman AH, van der Wurff AA, Osieka R, Buettner R, Hillen HF, Ramaekers FC

Unknown primary adenocarcinoma (UPA) comprises a group of heterogeneous cancers of great clinical and biological interest. UPA presents as metastatic disease without a detectable primary site after medical workup. Here we investigated whether or not a clonal relationship exists between multiple tumors within individual UPA patients. A molecular resemblance would argue for an early clonal outgrowth of tumor cells from the primary lesion, a mutual feature observed within this group of neoplasms. In 14 patients with UPA multiple tumors, obtained at autopsy, were analyzed by molecular allelotyping and immunohistochemistry. In addition, tumors of 4 patients could be analyzed by comparative genomic hybridization (CGH). Similar genetic and phenotypic profiles were used as indicator for a clonal relationship, whereas different profiles implicate independent tumors. The molecular data indicated that the multiple lesions in the 14 UPA patients, including the primary tumors, are clonally related. In agreement with the theory of tumor progression, some metastatic lesions showed additional genetic alterations besides the characteristics that were shared with the primary tumor. Furthermore, 8 UPA patients had tumors with a high frequency of allelic loss and/or imbalance (FALI; 43-71%), while 6 patients demonstrated a lower FALI (14-29%), suggesting the occurrence of chromosomal instability in the former group. Our data provide molecular evidence for a clonal relationship between multiple metastases and the primary tumor within individual UPA patients, independent of the anatomical origin of the cancer. This finding is in agreement with the suggestion that tumor progression is rapid in UPA patients, limiting the chance of clonal divergence. The identification of 2 groups of UPAs with either a high or low FALI indicates that chromosomal instability is not the only driving force behind early tumor cell dissemination. Thus, other molecular mechanisms must underlie the common biology of these tumors. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18561313
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.
To: mesothelioma77@gmail.com


[1]J Cancer Res Clin Oncol. 2008 Jun 17;
Ruckhäberle E, Karn T, Hanker L, Gätje R, Metzler D, Holtrich U, Kaufmann M, Rody A

PURPOSE: Multidrug resistance (MDR) has been linked to sphingolipid metabolism and preclinical data ascribe glucosylceramide synthase (GCS) a major role for MDR especially in breast cancer cells but no profound data are available on the expression of this potential therapeutic target in clinical breast cancer specimens. METHODS: We analyzed microarray data of GCS expression in a large cohort of 1,681 breast tumors. RESULTS: Expression of GCS was associated with a positive estrogen receptor (ER) status, lower histological grading, low Ki67 levels and ErbB2 negativity (P

___
Source: http://www.hubmed.org/display.cgi?uids=18560890
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Modified radical mastectomy with axillary dissection using the electrothermal bipolar vessel sealing system.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Modified radical mastectomy with axillary dissection using the electrothermal bipolar vessel sealing system.
To: mesothelioma77@gmail.com


[1]Arch Surg. 2008 Jun; 143(6): 575-80; discussion 581
Manouras A, Markogiannakis H, Genetzakis M, Filippakis GM, Lagoudianakis EE, Kafiri G, Filis K, Zografos GC

HYPOTHESIS: The use of the electrothermal bipolar vessel sealing system is feasible, safe, and effective in modified radical mastectomy with axillary dissection in terms of lymph vessel sealing, hemostasis, and perioperative complications. DESIGN: Prospective study. SETTING: University surgical department. PATIENTS: Between January 1, 2003, and December 31, 2003, 60 patients with locally advanced breast cancer (T2 or T3) admitted for modified radical mastectomy with axillary dissection were included in this study. The entire procedure was performed by the same surgical team using the electrothermal bipolar vessel sealing system. MAIN OUTCOME MEASURES: Final outcome, operative time, hospitalization stay duration, intraoperative blood loss, postoperative mastectomy and axillary drainage volume and duration, and postoperative complications (seroma, bleeding, skin burn, hematoma, lymphedema, pneumothorax, and wound infection or necrosis). RESULTS: The mean (SD) intraoperative blood loss was 45 (12) mL, and the mean (SD) operative time was 105 (7) minutes. No postoperative bleeding, seroma, hematoma, lymphedema, or other complications occurred. The mean (SD) mastectomy and axillary drainage volumes were 20 (8) and 155 (35) mL, respectively, and the mean (SD) drainage durations were 1.3 (0.2) and 2.7 (0.5) days, respectively. The mean (SD) hospital stay was 3.7 (0.6) days. CONCLUSIONS: In this first report (to our knowledge) of modified radical mastectomy with axillary dissection using the electrothermal bipolar vessel sealing system, the technique was feasible, safe, and effective. The device simplified the surgical procedure, while achieving efficient lymph vessel sealing and hemostasis. Compared with historical data regarding the conventional or harmonic scalpel, this technique seems to result in reduced operative time, perioperative blood loss, drainage volume and duration, and incidence of seroma or lymphedema. Prospective randomized controlled studies are necessary to evaluate the effect of this technique on perioperative complications.



___
Source: http://www.hubmed.org/display.cgi?uids=18559751
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Researchers Optimistic About New Therapy For Lung Cancer (Medical News Today)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Researchers Optimistic About New Therapy For Lung Cancer (Medical News Today)
To: mesothelioma77@gmail.com


An article in the July edition of The Lancet Oncologysuggests that a common treatment for liver cancer - radiofrequencyablation - can also be used to treat lung cancer. A team of Europeanand American researchers calls for randomized controlled trials inorder to more robustly investigate this minimally invasive procedurefor cancer treatment.

Fri, 20 Jun 2008 08:15:52 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11netr8lv/*http%3A//www.medicalnewstoday.com/articles/112052.php
--
 
 

Fwd: Antihormone therapy in recurrent metastatic breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Antihormone therapy in recurrent metastatic breast cancer.
To: mesothelioma77@gmail.com


[1]JAMA. 2008 Jun 18; 299(23): 2745; author reply 2745
Pritchard KI





___
Source: http://www.hubmed.org/display.cgi?uids=18559999
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Non-Surgical Approach Can Treat Lung Cancers (HealthDay via Yahoo! News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Non-Surgical Approach Can Treat Lung Cancers (HealthDay via Yahoo! News)
To: mesothelioma77@gmail.com


WEDNESDAY, June 18 (HealthDay News) -- A minimally invasive procedure normally used to treat liver cancer also holds promise for lung cancer patients, according to a new study.

Wed, 18 Jun 2008 13:01:32 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=12menkona/*http%3A//news.yahoo.com/s/hsn/20080618/hl_hsn/nonsurgicalapproachcantreatlungcancers
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Epigenomics Successfully Completes Larger Clinical Study in Early Lung Cancer Detection (PrimeNewswire via Yahoo! Finance)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Epigenomics Successfully Completes Larger Clinical Study in Early Lung Cancer Detection (PrimeNewswire via Yahoo! Finance)
To: mesothelioma77@gmail.com


BERLIN and SEATTLE, June 18, 2008 -- Epigenomics AG , a molecular diagnostics company focusing on the development and commercialization of products for cancer detection based on DNA methylation, today announced that it successfully completed a larger clinical study in its lung cancer program.

Wed, 18 Jun 2008 07:12:56 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11eqctkpc/*http%3A//biz.yahoo.com/pz/080618/144892.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 17;
Yao H, Wang H, Zhang Z, Jiang BH, Luo J, Shi X

Previous studies show that a number of natural compounds from our diet have anticancer effects. Sulforaphane is the most characterized isothiocyanates (ITCs), which are identified in cruciferous vegetables. Sulforaphane is viewed as a conceptually promising agent in cancer prevention. Because of its ability to induce cancer cell apoptosis, it inhibits progression of benign tumors to malignant tumors and interrupts metastasis. However, the effect of sulforaphane on tongue cancer cell proliferation has not yet been reported, and the mechanisms that sulforaphane inhibits cancer development are still unclear. Hypoxia-inducible factor 1 (HIF-1) expression is associated with tumorigenesis and angiogenesis. It regulates the expression of many genes including vascular endothelial growth factor (VEGF), inducible nitric oxide synthase, and lactate dehydrogenase A. In our study, we investigated the effects of sulforaphane on expression of hypoxia-inducible factor-1alpha (HIF-1alpha), which was overexpressed in many human malignant tumors, human tongue squamous cell carcinoma and prostate cancer DU145 cells. Sulforaphane inhibited hypoxia induced expression of HIF-1alpha via inhibiting synthesis of HIF-1alpha. Sulforaphane was also found to inhibit hypoxia induced HIF-1alpha expression through activating JNK and ERK signaling pathways, but not AKT pathway. Inhibition of HIF-1alpha by sulforaphane resulted in decreasing expression of VEGF. Taken together, these results suggest that sulforaphane is an effective chemopreventive compound against tongue cancers and prostate cell angiogenesis in vitro, and that the HIF-1alpha target provides a new sight into the mechanisms of sulforaphane's inhibition against tumor cell proliferation. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18561315
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Psychological distress and its correlates in ovarian cancer: a systematic review.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Psychological distress and its correlates in ovarian cancer: a systematic review.
To: mesothelioma77@gmail.com


[1]Psychooncology. 2008 Jun 17;
Arden-Close E, Gidron Y, Moss-Morris R

Objective: Ovarian cancer is often diagnosed at an advanced stage, and consequently high levels of distress are often experienced. It is necessary to understand the factors associated with psychological distress in order to guide interventions to target those factors. The purpose of this systematic review was therefore to identify correlates of psychological distress in ovarian cancer.Methods: Included studies had to be quantitative and empirical, with standardized measures of psychological distress (anxiety or depression), and to present results for ovarian cancer patients specifically. Standard systematic search methods were used. Information about design, ovarian cancer sample size, disease stage, time since diagnosis, measures of distress used and findings was extracted from each study. The studies were quality assessed using experimenter-defined criteria as good, average and poor quality. Strength of the evidence (strong, some, inconclusive) was based on the quality and consistency of findings.Results: Eighteen studies meeting the inclusion criteria were identified. There was strong evidence for a relationship between younger age, being diagnosed with more advanced disease, more physical symptoms and shorter time since diagnosis with increased levels of anxiety and/or depression. Additional factors (e.g. immune) tested in a few studies also emerged as correlates of distress.Conclusions: Demographic, disease and quality of life factors correlated with distress. However, too few studies assessed possible psychological and immunological correlates, which could be potentially modified and should be assessed in future studies. Copyright (c) 2008 John Wiley & Sons, Ltd.



___
Source: http://www.hubmed.org/display.cgi?uids=18561287
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Ex-BBC presenter has lung cancer (BBC News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Ex-BBC presenter has lung cancer (BBC News)
To: mesothelioma77@gmail.com


Former BBC Wales sports presenter Bob Humphrys says his lung cancer diagnosis seems "rather unjust".

Tue, 17 Jun 2008 15:20:34 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11phpkfg0/*http%3A//news.bbc.co.uk/go/rss/-/1/hi/wales/7459477.stm
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program.
To: mesothelioma77@gmail.com


[1]Clin Cancer Res. 2008 Jun 15; 14(12): 3643-5
Steeg PS





___
Source: http://www.hubmed.org/display.cgi?uids=18559575
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.
To: mesothelioma77@gmail.com


[1]PLoS ONE. 2008; 3(6): e2518
Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris P, Guichard G, Briand JP, Courty J, Hovanessian AG

BACKGROUND: Emerging evidences suggest that nucleolin expressed on the cell surface is implicated in growth of tumor cells and angiogenesis. Nucleolin is one of the major proteins of the nucleolus, but it is also expressed on the cell surface where is serves as a binding protein for variety of ligands implicated in cell proliferation, differentiation, adhesion, mitogenesis and angiogenesis. METHODOLOGY/PRINCIPAL FINDINGS: By using a specific antagonist that binds the C-terminal tail of nucleolin, the HB-19 pseudopeptide, here we show that the growth of tumor cells and angiogenesis are suppressed in various in vitro and in vivo experimental models. HB-19 inhibited colony formation in soft agar of tumor cell lines, impaired migration of endothelial cells and formation of capillary-like structures in collagen gel, and reduced blood vessel branching in the chick embryo chorioallantoic membrane. In athymic nude mice, HB-19 treatment markedly suppressed the progression of established human breast tumor cell xenografts in nude mice, and in some cases eliminated measurable tumors while displaying no toxicity to normal tissue. This potent antitumoral effect is attributed to the direct inhibitory action of HB-19 on both tumor and endothelial cells by blocking and down regulating surface nucleolin, but without any apparent effect on nucleolar nucleolin. CONCLUSION/SIGNIFICANCE: Our results illustrate the dual inhibitory action of HB-19 on the tumor development and the neovascularization process, thus validating the cell-surface expressed nucleolin as a strategic target for an effective cancer drug. Consequently, the HB-19 pseudopeptide provides a unique candidate to consider for innovative cancer therapy.



___
Source: http://www.hubmed.org/display.cgi?uids=18560571
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations.
To: mesothelioma77@gmail.com


[1]Support Care Cancer. 2008 Jun 17;
Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WP

OBJECTIVE: The objective of this prospective multicenter study was to obtain insight into the severity and burden of hair loss among cancer patients treated with chemotherapy. In addition, we described the effectiveness and burden of scalp cooling and the satisfaction with wigs, with hair regrowth, and with body image. MATERIALS AND METHODS: Breast cancer patients treated with (n = 98) and without (n = 168) scalp cooling completed questionnaires before chemotherapy and 3 weeks and 6 months after completion of chemotherapy. RESULTS: Scalp cooling was effective in preventing chemotherapy-induced hair loss in 32 of 62 available patients (52%). Even though patients knew hair loss was temporary, it was a burden to 54% of them (n = 100). Scalp cooling was a burden for only 17 out of 51 patients (33%). Most patients who used a wig or head cover were satisfied with it (82%, n = 126). Patients were moderately satisfied with the regrowth of their hair after chemotherapy (mean 11.6; SD 2.53; range 0-20). Successfully cooled patients rated their hair as less important for their body image compared to patients who did experience hair loss (p = 0.014). DISCUSSION: Chemotherapy-induced hair loss is perceived as burdensome. It may be prevented by offering scalp cooling which is often an effective method to prevent this form of hair loss and is tolerated well by patients. However, if possible, scalp-cooling techniques should be improved and their effectiveness should be increased because if scalp cooling is unsuccessful, patients' rate their hair loss as more burdensome compared to noncooled patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18560904
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Predicting breast cancer risk: implications of a "weak" family history.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Predicting breast cancer risk: implications of a "weak" family history.
To: mesothelioma77@gmail.com


[1]Fam Cancer. 2008 Jun 17;
Anderson E, Berg J, Black R, Bradshaw N, Campbell J, Cetnarskyj R, Drummond S, Davidson R, Dunlop J, Fordyce A, Gibbons B, Goudie D, Gregory H, Hanning K, Holloway S, Longmuir M, McLeish L, Murday V, Miedzybrodska Z, Nicholson D, Pearson P, Porteous M, Reis M, Slater S, Smith K, Smyth E, Snadden L, Steel M, Stirling D, Watt C, Whyte C, Young D

Published guidelines adopted in many countries recommend that women whose family history of breast cancer places them at a risk >/=1.7 times that of the age-matched general population, should be considered for inclusion in special surveillance programmes. However validation of risk assessment models has been called for as a matter of urgency. The databases of the four Scottish Familial Breast Cancer clinics and the Scottish Cancer Registry have been searched to identify breast cancers occurring among 1,125 women aged 40-56, with family histories placing them below the "moderate" level of genetic risk. The observed incidence over 6 years was compared with age-specific data for the Scottish population. Our findings confirm that when there are two affected relatives (one first degree) the relative risk (RR) exceeds 1.7 regardless of their ages at diagnosis. When only one (first degree) relative was affected at any age from 40 to 55, the RR does not reach 1.7 if that relative was a mother but exceeds it if the relative was a sister. The probable explanation is that sisters are more likely than mother/daughter pairs to share homozygosity for a risk allele. Surveillance programmes might therefore accommodate sisters of women affected before age 55. Evidence that "low penetrance" alleles contributing to breast cancer risk may be recessive should be taken into account in strategies for identifying them.



___
Source: http://www.hubmed.org/display.cgi?uids=18560993
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: The next step in reducing the toll of tobacco

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: The next step in reducing the toll of tobacco
To: mesothelioma77@gmail.com

The Star article, 'Cigarette sales dive 17.8% after tax hike,' and the June 10 editorial regarding the reduction in cigarette sales and the Quit 2 Win campaign explained how the tobacco tax increase has ...

Sun, 15 Jun 2008 07:00:00 GMT

---

Source: http://www.indystar.com/apps/pbcs.dll/article?AID=2008806150337
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Philanthropist-activist Stewart Mott dead at 70

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Philanthropist-activist Stewart Mott dead at 70
To: mesothelioma77@gmail.com

NEW YORK -- Stewart Mott, the Flint-raised eccentric and freethinking philanthropist who helped bankroll the presidential campaigns of Eugene McCarthy and George McGovern, has died.

Sun, 15 Jun 2008 07:00:00 GMT

---

Source: http://www.freep.com/apps/pbcs.dll/article?AID=2008806150592
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc